Navigation Links
PRA International Appoints Shannon as CEO
Date:12/14/2009

RALEIGH, N.C., Dec. 14 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, is pleased to announce that Colin Shannon, who has served as President and Chief Operating Officer of PRA since May 2007, has been appointed President, Chief Executive Officer (CEO) and Director, effective Jan. 1, 2010.

"It is with great pleasure that we welcome Colin to this top executive role," said Chairman of the Board, Melvin D. Booth. "Having worked closely with Colin for the last two and one-half years, it is clear that he is the ideal person to lead our Company. This planned transition ensures that PRA will maintain its momentum in driving 'evidence-based decision making' into clinical development and its continued focus on building a talent pool of clinical professionals." Jean-Pierre L. Conte, Chairman and Managing Director of Genstar Capital, LLC, the principal investor in PRA, further commented, "Colin has brought to PRA a depth of industry knowledge and a leadership style that fits well with our culture. We are confident PRA will continue to flourish under his leadership."

Prior to joining PRA, Mr. Shannon was employed by Pharmaceutical Product Development, Inc. (PPD) for twelve years in key executive positions, the last being Executive Vice President, Global Clinical Operations. Before joining PPD, Mr. Shannon held financial positions with various other companies. He holds a master's degree in business administration from London's City University and is a Fellow Member of the Chartered Association of Certified Accountants.

"I always had a deep respect for the PRA organization and its reputation within the industry," said Mr. Shannon. "Since joining PRA, the executive team has focused on developing our current mission and vision. As a result, my respect for PRA has deepened even more. I am truly impressed with the quality and commitment of the entire PRA team. Working together, we will buil
'/>"/>

SOURCE PRA International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nonprofit Partners With PR Company and Gains International Attention
2. Medical Travel Quality Alliance to Certify Medical Tourism Agents for Safer, Quality Health Care for Traveling International Patients
3. Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange
4. Oncologist at the Childrens Hospital of Philadelphia to Chair International Childhood Cancer Organization
5. Reliv International Hires Director of Strategic Development
6. BridgeGate International Announces New Integration and Interoperability Training Program
7. AVIVA's Private Health Insurance Products Solutions Go International
8. Mark Samuel, CEO & Founder, IMPAQ Accountability Business Consultants Inc., to Present at 14th ICF Annual International Conference
9. Northern California Cancer Centers Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research
10. Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board
11. The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, Former FDA ... , Having FDA-regulated products held at ports costs time, money and the competitive ... or even destruction — of products, an FDA insider shows manufacturers how to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital ... catheter that was developed for targeted delivery of fluids to selected sites in ... at Florida Hospital Tampa with the device that provides direct, local delivery of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in ... 17th at Ford Field in Detroit and the second match will occur in Birmingham, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to ... Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based call ... display logic shows the script components to the agent only when wanted, and allows ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... In a new study, researchers have discovered that suffering from ... which is a dangerous condition in which blood clots form ... cause an increase in the risk of heart attacks and ... of more than three million patient records from across the ...
... deal with crimes committed by drug addicts have been extended ... be started all across the country. // The drug courts ... 2002. These will undergo further monitoring by the Scottish Executive’s. ... indicated that there were no significant difference in re-conviction rates ...
... according to the decision taken by the Tibetan government in ... ,'Under an integrated development programme by 2007, $25 ... of the Tibetan government led by the Dalai Lama. ... India and some of them have taken around 20,000 acres ...
... of the brain plays an important role in distinguishing ... at the National Institutes of Health's (NIH) National Institute ... scans has found how the brain's outer layer, cortex, ... childhood stage, reflecting a high-level thinking circuitry. On the ...
... pain killing medication helps by halting the production of an ... cancer. The name of the painkiller is Nimesulide. // ... scientists found that derivatives of nimesulide stopped the production of ... of cancer is the most common breast cancer in postmenopausal ...
... Rudland, Dr Guozheng Wang and Dr Roger Barraclough from the ... new gene that causes the spread of cancer. // An ... is the main cause for the spread of cancerous cells ... If S100P is present it trigger the rapid spread of ...
Cached Medicine News:Health News:Cortex Of Youth With Superior IQ Matures Fast 2Health News:Pain-killer Drug Can Help Fight Breast Cancer 2
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Argos Therapeutics, Inc. today announced that its late scientific co-founder ... Nobel Prize in medicine for the discovery of dendritic cells ... Steinman,s discovery of dendritic cells and his research of dendritic ... immunity have led to the development of Argos, core technology, ...
... Ingenious Med welcomes Chief Financial Officer, Mark Adams as ... responsible for the company,s financial, accounting, treasury and ongoing ... executive with high growth companies such as Ingenious Med," ... financial background and experience will bring tremendous value to ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2New Chief Financial Officer, Mark Adams, Joins Ingenious Med 2
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... From solution to cell based assays, ... any non-isotopic method of detection, Fusion is ... requirements plus the capability to use the ... detection modes in one system: Reads ...
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature ...
Medicine Products: